Fr1da Early Diagnosis and Care of Type 1 Diabetes

NCT04039945 · tracked via the Priya Life Science Germany tracker

Sponsor

Helmholtz Zentrum München

Phase

Observational

Started

2015-02

Last updated

2024-12-17

Condition(s) studied

Type 1 Diabetes Mellitus

Study summary

The Fr1da study: "Early diagnosis and care of type 1 diabetes" aims to carry out a comprehensive, population-based screening for the early diagnosis of type 1 diabetes as part of the U7 to U11 preventive medical check-up for children or between the ages of 2 and 10 years in Bavaria and to implement it in other federal states. Screening is recommended at two time points: 1st screening at the age of 3 years (U7a) and 2nd screening at the age of 7 years (U10). In addition, relatives of patients with type 1 diabetes between the ages of 1 and 21 can be screened repeatedly at intervals of 3 to 5 years for an early-stage of type 1 diabetes.

Eligibility

Sex

ALL

Min age

2 Years

Max age

10 Years

Healthy volunteers

Accepted

written informed consent by one custodial parent

Primary outcome measure(s)

presence of multiple islet autoantibodies — up to 3 years
multiple islet autoantibodies (IAA, GADA, IA-2A and/or ZnT8A)

Trial sites (1)

Facility	City	Region	Status
Institut für Diabetesforschung, Helmholtz Zentrum München	Munich	Germany	Recruiting

More Helmholtz Zentrum München trials in Germany

Freder1k-Study - Testing Infants for Type 1 Diabetes Risk Recruiting

Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity Active, not recruiting

Other trials for the same condition

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) Recruiting

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) Active, not recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04039945 on ClinicalTrials.gov ↗ ← All trials in Germany